Apr 2014

“QuickNavi Strep A” April 14 Market Launch in Japan Test Kit for the Rapid Detection of Group A Beta-hemolytic Streptococcal Antigen


  • Rapid (five minutes) and highly sensitive test for the detection of infection with group A beta-hemolytic Streptococcus – approximately 90 percent of positive infections can be detected within two minutes. Preparation of the test sample is a simple one-step process.
  • The main symptoms of group A Streptococcus infection are fever, pharyngitis, and tonsillitis. Group A Streptococcus infects individuals across a wide range of ages. It is a perennial bacteria, and circulates mainly in early spring and in winter.
  • The “QuickNavi” series of test kits is characterized by simple operation and rapid, sensitive detection capability, and the launch of QuickNavi Strep A adds group A Streptococcus, a rapid test kit for which has been in great demand, to the QuickNavi brand line.

Otsuka Pharmaceutical Co., Ltd. announced it will on April 14, 2014 in Japan launch the “QuickNavi Strep A” rapid test kit for beta-hemolytic group A Streptococcus. This will be the sixth diagnostic test kit in the “QuickNavi” series of kits, which are noted for their simple operation and rapid detection capability.

The “QuickNavi Strep A” kit is a device type kit with a detection line that is easy to see. Preparation of the test solution is a simple, one-step process, unlike with existing products. Children are the primary target population for testing, and the use of a flocked swab makes it easier to collect throat samples than a conventional cotton swab. Detection sensitivity is high, and detection is rapid – five minutes. Normally, approximately 90 percent of positive infections can be detected within two minutes.

Information in this news release was current as of the original release date.


Otsuka Pharmaceutical Co., Ltd. (OPC) is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health. 

In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs for several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. 

Otsuka Canada Pharmaceutical Inc. (OCPI) is an innovative, fast-growing health care company that commercializes Otsuka medicines in Canada. OCPI aims to improve the quality of life and health of patients through its commitments to neuroscience, cardiovascular health, oncology and nephrology. OCPI was established in 2010, with headquarters in Saint-Laurent, Quebec.


OCPI is part of Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd., based in Tokyo, Japan. The Otsuka group of companies employed 45,000 people worldwide and had consolidated sales of approximately CAD 14.5 billion (USD 11 billion) in 2016.

About Us
Contact Us

1 888 997-9017
514 332-3001

2250 Alfred-Nobel Boulevard,
St-Laurent, Quebec,
Suite 301
H4S 2C9